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Abstract: It has been suggested that oxidative stress activates various intracellular 
signaling pathways leading to secretion of a variety of pro-inflammatory cytokines and 
chemokines. SHP-1 is a protein tyrosine phosphatase (PTP) which acts as a negative 
regulator of immune cytokine signaling. However, intracellular hydrogen peroxide (H2O2), 
generated endogenously upon stimulation and exogenously from environmental oxidants, 
has been known to be involved in the process of intracellular signaling through inhibiting 
various PTPs, including SHP-1. In this study, we investigated the potential role of 
astaxanthin, an antioxidant marine carotenoid, in re-establishing SHP-1 negative regulation 
on pro-inflammatory cytokines secretion in U-937 cell line stimulated with oxidative 
stimulus. ELISA measurement suggested that ASTA treatment (10 µM) reduced   
pro-inflammatory cytokines secretion (IL-1β, IL-6 and TNF-α) induced through H2O2, 
(100 µM). Furthermore, this property is elicited by restoration of basal SHP-1 protein 
expression level and reduced NF-κB (p65) nuclear expression, as showed by western 
blotting experiments. 
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1. Introduction 
It is known that excess of reactive oxygen species (ROS) is associated to inflammation, growth and 
vasoconstriction contributing to vascular injury in many cardiovascular diseases, such as hypertension, 
hyperlipidemia, and diabetes [1–3]. Inflammation, a self-defense reaction against various pathogenic 
stimuli, it may become a harmful self-damaging process, if it transforms to chronic inflammation [4]. 
Carotenoids are phytochemicals considered beneficial in the prevention of a variety of major   
diseases [5,6]. The marine carotenoid astaxanthin (ASTA) is naturally found in a wide variety of living 
organisms, such as microalgae, fungi, and crustaceans [7]. Astaxanthin (3,3-dihydroxy-beta, 
beta-carotene-4,4-dione) belongs to the xanthophyll subclass of carotenoids. Several studies have 
demonstrated that ASTA possesses powerful antioxidant properties, both in vitro and in vivo, 
especially as an inhibitor of LDL oxidation [8]. Evidence has suggested that the action of carotenoids 
on immunity and diseases may be mediated, at least in part, by their ability to quench and/or blench 
ROS [9]. In recent years, a number of studies on astaxanthin have demonstrated its in vitro and in vivo 
antioxidant effect, for example, the quenching effect on singlet oxygen, a strong scavenging effect on 
superoxide, hydrogen peroxide, and hydroxyl radicals and an inhibitory effect on lipid peroxidation. 
The specific molecular mechanisms of its actions are not yet established [10,11]. Protein tyrosine 
phosphorylation (PTPs) plays a variety of significant roles in cell signaling transduction, physiological 
functions, and pathological processes [12,13]. In the PTP family, a subgroup of cytoplasmic PTPs 
characterized by containing two Src homology 2 (SH2) N-terminal domains and a C-terminal  
protein-tyrosine phosphatase domain are referred to as SHP. They are intimately involved in several 
cellular activities, such as cytoskeletal maintenance, cell division, and cell differentiation [14,15]. 
Phosphorylation of proteins serves to alter their activity, providing a simple and mostly reversible 
change in molecular function. Interest in the diverse biology of protein tyrosine phosphatases that are 
encoded by more than 100 genes in the human genome continues to grow at an accelerated pace [16]. 
In particular, two cytoplasmic protein tyrosine phosphatases composed of two Src homology 2 (SH2) 
N-terminal domains and a C-terminal protein-tyrosine phosphatase domain referred to as SHP-1 and 
SHP-2 are known to govern a host of cellular functions [17,18]. 
Most recently, SHP-1 deficiency was found to increase inflammatory gene expression and enhance 
activation of transcription factor STAT6, STAT1, and NF-κB in PBMC and macrophages of patients 
with multiple sclerosis [19,20]. Because oxidants are released early in inflammation and have been 
found to regulate transcription factors, the aim of the present study was to evaluate the in vitro effect 
of carotenoid astaxanthin (ASTA) in inflammation through the evaluation of cytokine release, SHP-1 
expression and reactive oxygen species production on U937 cells stimulated with H2O2. 
2. Results and Discussion 
2.1. Cell Viability 
It has been well established that oxidative agents, such as H2O2, can induce cell death [21]. In order 
to investigate the influence of ASTA on immunitary cell viability, we treated U937 cells with H2O2, 
and examined its effects. Since a concentration of 100 µM H2O2 and an incubation time of 12 h were 
previously identified as optimal time and concentration (data not shown) for the induction of Mar. Drugs 2012, 10  
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deleterious effects on U937 cell viability, these conditions were selected for the rest of experiments. 
The viability of cells exposed to 100 µM H2O2 for 12 h was 61.5 ± 2.8% vs. 96.0 ± 2.8% of the control 
value, while the viability of cells that were pre-treated for 24 h with ASTA at a concentration of 10 μM 
prior to 12 h exposure to H2O2 increased significantly to 78.1 ± 1.9% (p < 0.01) (Table 1). These 
results indicate that the viability of H2O2-treated cells decreased significantly, but that the ASTA 
exerted a protective effect against the H2O2-induced cytotoxicity. 
Table 1. Effect of astaxanthin (ASTA) upon cell viability evaluated by MTT assay. U937 
cells were pre-treated with ASTA (24 h, 10 µM) and followed by adding 100 µM H2O2. 
Data are mean ± SD (n = 6). 
  Before Incubation (%)  After Incubation (%) 
CTRL cells  96.9 ± 2.4  96.0 ± 2.8 
H2O2 100 µM    61.5 ± 2.8 * 
H2O2 100 µM + ASTA 10 µM    78.1 ± 1.9 
# 
ASTA 10 µM    97.0 ± 2.2 
* p < 0.01 vs. control cells; 
# p < 0.01 vs. H2O2 treated cells. 
2.2. Cytokines Elisa 
Oxidative stress has been shown to promote the production of several cytokines, including   
pro-inflammatory cytokines IL-1β, IL-6 and TNF-α. U937 cells were treated with either H2O2 or 
ASTA to investigate the characteristics of pro-inflammatory cytokines production. The single 
treatment with H2O2 (100 µM) was made for 12 h of culture, whereas the single treatment with ASTA 
(10 µM) was performed during the 24 h culture. In the combined treatment experiment, U937 cells 
were treated with 10 µM of ASTA for the first 24 h and then with only 100 µM H2O2 for 12 h. The  
IL-1β, IL-6 and TNF-α secretion was intensely induced by stimulating the cells with H2O2 compared 
with the control, but was significantly lower when pre-incubated for 24 h with ASTA before   
H2O2 stimulation (Figure 1). 
Figure 1. IL-1β, IL-6 and TNF-α levels in U937 cells treated with H2O2 (100 µM) and 
treated or non-treated with astaxanthin (ASTA, 10 µM). Cytokines levels resulted 
augmented after H2O2 treatment. Co-treatment with ASTA significantly reduced cytokines 
release, while ASTA alone not affect cytokines released in the culture medium. Values are 
expressed as pg/mL. Each value represents the mean ± SD of three independent 
experiments (* p < 0.05 vs. H2O2 treated cells, 
# p < 0.05 vs. control cells). 
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Figure 1. Cont. 
 
2.3. Effect of H2O2 and ASTA on the NF-κB Activity in U937 Cells 
Reactive Oxygen Species (ROS) may activate nuclear factors, such as NFkB, leading to the 
production of pro-inflammatory cytokines, which in turn enhance inflammation and, therefore, the 
generation of other reactive species [22]. In most cases, NF-κB exists in a heterodimeric form 
composed of p65 (or RelB) and p50. Furthermore, phosphorylation of the p65 subunit at Ser 536 is 
associated with activation of NF-κB [23,24]. To identify the NF-κB activation and nuclear 
translocation after H2O2 stimulation, the phosphorylation levels of p65 subunit were measured by 
western blot analysis using a phospho-p65-specific Ab anti p-Ser-536 in U937 cells nuclear protein 
extracts after H2O2 treatment. Also, to test whether the ASTA affect the H2O2 induced activation of 
NF-κB, U937 cells were pre-treated with ASTA and then stimulated with H2O2 for Western blot 
analysis using a phospho-p65-specific pAb. Figure 2 showed that nuclear translocation of NF-κB 
containing the p-p65 subunit was strongly induced H2O2 treatment, but blocked by ASTA   
pre-treatment. These data suggest NF-κB involvement in ASTA reduction of pro-inflammatory 
cytokines secretion induced through H2O2 treatment. 
Figure 2. Western blotting analysis of phosphorylated subunit p65 of nuclear factor   
kappa-light-chain-enhancer  of activated B cells (NF-κB) expression in U937 nuclear 
protein extracts. Cells were pre-treated or not with astaxanthin (ASTA, 10 µM) and 
following treated with H2O2. Densitometric analysis is expressed as mean ± SD intensity of 
optical density (IOD) obtained by three independent experiments (* p < 0.05 vs. H 2O2 
treated cells, 
# p < 0.05 vs. control cells).  
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2.4. Effect of H2O2 and ASTA on SHP-1 Expression and Phosphatase Activity in U937 Cells 
Several reports showed inhibitory effect for SHP-1 phosphatase activity on cytokines   
secretion [25]. In order to investigate a role for SHP-1 in eliciting ASTA effects in U937 cells, western 
blot using specific anti-SHP-1 pAb experiments were performed. As shown in Figure 3A treatment 
with H2O2 strongly down-regulated SHP-1 protein expression. Pre-incubation with ASTA restored 
SHP-1 basal levels, showing a negative correlation between p65 nuclear translocation and SHP-1 
expression. Following this, in order to test whether SHP-1 is involved in the ASTA-mediated 
inhibition of NF-κB activation, western blot experiments for p-p65 on U937 nuclear extracts protein 
were performed in the presence of a specific inhibitor of SHP-1 (sodium stibogluconate, SS, 10 µM). 
Pre-incubation with SS blocked the ASTA-mediated inhibition of NF-κB activity (Figure 3B). 
Figure 3. (A) Expression of SHP-1 protein in representative Western blot experiments 
(upper). At the bottom, relative expression of SHP-1 (mean ± SD) in U937 cells pre-treated 
or not with astaxanthin (ASTA, 10 µM), stimulated with H2O2 (100 µM) or ASTA alone 
and in control cells. Each immunoreactive band was analyzed by densitometry and 
normalized to β-actin levels. (B) At the upper, representative Western blotting experiments 
of phosphorylated subunit p65 of NF-κB in U937 nuclear protein extracts. Cells were   
pre-treated with ASTA alone or with ASTA and sodium stibogluconate (SS, 10 µM) and 
following treated with H2O2 (bottom). Densitometric analysis is expressed as mean ± SD 
intensity of optical density (IOD) obtained by three independent experiments (* p < 0.05 vs. 
H2O2 treated cells, 
# p < 0.05 vs. control cells, 
§ p < 0.05 vs. ASTA + H2O2 treated cells). 
 
Moreover, pre-incubation with selective SHP-1 inhibitor, blocked ASTA down-regulation of H2O2 
induced cytokines release (Table 2). These data indicate that ASTA blocked the H2O2 mediated 
activation of NF-κB and its downstream cytokines secretion through modulating SHP-1 expression. Mar. Drugs 2012, 10  
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Table 2. IL-1β, IL-6 and TNF-α levels in U937 cells treated with H2O2 (100 µM) + ASTA 
(10 µM) and pre-incubated or not with sodium stibogluconate (SS, 10 µM). Cytokines 
released in the culture medium resulted significantly augmented after pre-treatment with 
SS. Values are expressed as pg/mL. Each value represents the mean ± SD of three 
independent experiments. 
 IL-1β (pg/mL)  IL-6 (pg/mL)  TNF-α (pg/mL) 
CTRL cells  34.2 ± 4.9  7.1 ± 2.9  20.4 ± 8.6 
H2O2 100 µM  90.5 ± 4.5  66.7 ± 6.0  121.4 ± 11.1 
H2O2 100 µM + ASTA 10 µM  56.9 ± 8.3  41.5 ± 9.4  48.9 ± 12.2 
H2O2 100 µM + ASTA 10µM + SS 10 µM  88.9 ± 9.5 *  65.2 ± 4.2 *  122.9 ± 12.5 * 
* p < 0.05 vs. H2O2 + ASTA treated cells. 
3. Experimental Section 
3.1. Cell Culture 
U937 mononuclear cells were purchased from American Type Culture Collection (Manassas, VA, 
USA). The cells were cultured in a 5% CO2 atmosphere in RPMI 1640 medium (GIBCO, Invitrogen) 
containing 10% fetal calf serum, 100 ng/mL streptomycin, 100 U/mL penicillin and 2 mM   
L-glutamine. Cells derived from the same freeze-down batch were thawed, grown and seeded   
(at 2 × 10
5 cells per well) onto six-well tissue culture plates and cultured in medium with and without  
10 µM astaxanthin (ASTA), with and without sodium stigluconate (SS) and treated with H2O2  
(100 µM). ASTA was dissolved in dimethyl sulfoxide (DMSO) and diluted with the medium. The  
final concentration of DMSO in the medium was 0.5%. Control groups not contained ASTA and/or 
H2O2. Cell viability was determined by trypan blue dye exclusion and MTT assay (Biotium, Hayward, 
CA, USA). 
3.2. Reagents 
The primary antibodies used for Western blotting were rabbit anti-SHP-1, anti NF-κB and   
anti-p-NF-κB (p65) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and mouse anti-β-actin 
(A5441; Sigma-Aldrich, St. Louis, MO, USA). Astaxanthin was obtained by Sigma-Aldrich. Sodium 
stibogluconate was purchased from Merck (Darmstadt, Germany). 
3.3. Cytokines ELISA 
U937 cells were pretreated with ASTA for 24 h. After pre-incubation with ASTA, H2O2 was added 
to the wells. In other experiment pre-incubation was performed with ASTA and SS. The supernatants 
were collected and assayed using the Searchligth Elisa kit according to the manufacturer’s instructions 
(Thermo Fisher Scientific, Rockford, IL, USA.). Mar. Drugs 2012, 10  
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3.4. Western Blotting 
U937 cells were washed once in cold phosphate-buffered saline (PBS; 0.5 mol/L sodium phosphate, 
pH 7.5) and harvested by gentle scraping, and used to prepare total protein or nuclear extracts. Total 
protein extracts were prepared by treating cells with lysis buffer [50 mmol/L Tris–HCl pH 7.5, 0.4% 
Nonidet P-40 (NP-40), 120 mmol/L NaCl, 1.5 mmol/L MgCl2, 2 mmol/L phenylmethylsulphonyl 
fluoride (PMSF), 1 µg/mL leupeptin, 3 mmol/L NaF and 1 mmol/L dithiothreitol] for 30 min at 4 °C. 
Nuclear extracts were prepared according to Osborn et al. [24]. Cells were pelleted, frozen in dry 
ice⁄ethanol, resuspended in 75 µL of Buffer A (10 mmol/L HEPES pH 7.9, 10 mmol/L KCl,   
0.5 mmol/L EDTA, 1.5 mmol/L MgCl2, 0.2% NP-40 and 0.5 mmol/L PMSF) and placed on ice for  
10 min to allow lysis. Nuclei were pelleted by centrifugation at 3500 g for 10 min at 4 °C, resuspended 
in 1 mL of Buffer B (20 mmol/L HEPES pH 7.9, 400 mmol/L NaCl, 1.5 mmol/L MgCl2, 0.5 mmol/L 
EDTA, 25% glycerol and 0.5 mmol/L PMSF) and placed on a rocking platform for 30 min at 4 °C. 
The nuclear lysates were then clarified by centrifugation at 14,000 g for 20 min at 4 °C and the 
supernatants (nuclear extracts) collected. The protein concentrations of the extracts were determined 
using the Bradford method (Bio-Rad protein assay, Hercules, CA, USA). For Western blot analysis,  
50 µg of protein per lane was separated on a 4–12% NuPAGE gradient gel (Gibco Invitrogen),   
electro-transferred on to a nitrocellulose membrane and blocked with 10% skimmed milk in PBS 
containing 0.1% Tween-20. Blots were probed and incubated overnight at 4 °C with the rabbit 
polyclonal IgG anti-SHP-1, the rabbit polyclonal IgG anti-pNF-κB and NF-κB (p65) all at 0.2 µg/mL 
in Tris-buffered saline (TBS)/0.1% Tween-20. A rabbit antihuman monoclonal antibody recognizing 
the human β-actin was used as control in all experiments. Blots were then washed and incubated for  
1 h with goat antirabbit–horseradish peroxidase (Pierce Biotechnology, Rockford, IL, USA) diluted  
1:10,000 in TBS/0.1% Tween-20. Immunoblot signals were developed using the Super Signal Ultra 
chemiluminescence detection reagents (Pierce Biotechnology). The blot images were analyzed with a 
gel analysis software package (Gel Doc 1000; Bio-Rad, Milan, Italy). Data are expressed as   
mean ± SD intensity of optical density. 
3.5. Statistical Analysis 
The results are expressed as mean ± SD. Statistical analysis was performed using analysis of 
variance (ANOVA). The probability of null hypothesis of <5% (p < 0.05) was considered statistically 
significant. The comparison H2O2 vs. H2O2 + ASTA and H2O2 + ASTA vs. H2O2 + ASTA + SS was 
performed using post hoc test with the alpha level at 0.05. 
4. Conclusions 
It is well recognized that persistent inflammation contributes to the pathogenesis of many diseases, 
including cancer, heart disease and atherosclerosis [25–27]. The manipulation of the course and 
intensity of an inflammatory process may occur not only by using agents that inhibit activated   
“pro-inflammatory pathways”, but also through an approach to activate the natural anti-inflammatory 
processes, therefore it is essential to identify the metabolic pathways, sensitive to excessive tissue 
damage, which contribute to the resolution of inflammation. The development of new anti-inflammatory Mar. Drugs 2012, 10  
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drugs reflects the need to prevent excessive tissue damage that can be established as a result of the 
persistence of inflammation and at the same time, the need to better understand the processes that 
contribute to the control and resolution of inflammation. The main properties of astaxanthin inactivate 
harmful free radicals that are the basis of an inflammatory process. In the immune system, SHP-1 
plays critical roles in regulation of many receptor-mediated signaling cascades, and SHP-1 deficiency 
in mice causes spontaneous inflammation and autoimmunity [28,29]. For the first time our results 
show that astaxanthin most likely inhibits ROS-induced production of NF-κB transcription factor, 
which in turn effectively inhibits the production of inflammatory cytokines, through a restoration of 
physiological levels of SHP-1. Astaxanthin has potential and promising applications in human health 
because it represents the new frontier of therapy against free radicals [30]. Our future aim will be to 
demonstrate that the ASTA through the positive regulation of SHP-1 could represent a new therapeutic 
approach in relation to common inflammatory diseases, even for those affected with allergies cannot 
benefit from the use of Non-steroidal anti-inflammatory drugs (NSAIDs). In addition, in relation to 
these findings our goal is to propose the in vitro and in vivo evaluation of ASTA as a positive 
modulating factor in diseases such as rheumatoid arthritis, where persistent inflammation leads to 
constant and harmful use of anti-inflammatory molecules (NSAIDs and glucocorticoids). 
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